Characterization of n-butyl alcohol solubilized, breast tumor specific antigens recognized by a human autologous cytotoxic T-cell clone. 1988

T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
Department of Pathology, Sapporo Medical College, Japan.

We demonstrated previously the establishment of a human cytotoxic T-cell clone, TcHMC-1, under culturing with recombinant interleukin that showed the specific cytotoxicity against an autologous breast tumor cell line, HMC-1-8. In the present study, the autologous tumor specific antigens that could be involved in this cytotoxicity were extracted by using n-butyl alcohol and were analyzed for their biochemical profiles. The cytotoxicity of TcHMC-1 against HMC-1-8 was inhibited by adding OKT3 and OKT8 monoclonal antibodies into the cultures, or by pre-sensitizing HMC-1-8 target cells by anti-major histocompatibility complex class I monoclonal antibodies. This suggests that T-cell antigen receptor molecule complexes Ti/T3 on TcHMC-1 and corresponding specific tumor antigens on HMC-1-8 are involved in the cytotoxicity under the restriction of major histocompatibility complex class I products. Precultures of TcHMC-1 with crude n-butyl alcohol extracts from HMC-1-8 cells enhanced the cytotoxic potentials of this clone as seen as mixed lymphocyte tumor cell cultures. This enhancement was dependent on dosage of crude n-butyl alcohol extracts and these TcHMC-1 cells were still cytotoxic specifically for HMC-1-8 targets, but not for other allogenic tumor lines including K562. However, HMC-1-8 crude n-butyl alcohol extracts could not enhance DNA synthesis of TcHMC-1 as assessed by incorporation of [3H]thymidine in the cells. Biochemical purification studies demonstrated that the HMC-1-8 tumor specific antigens were eluted into fractions containing molecules with molecular weights of approximately 200,000 on Sephadex G-200 column chromatography. The antigens were further separated into the fraction that was eluted with 0.4-0.5 M NaCl in an ionic strength on Mono Q fast protein liquid chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of this fraction demonstrated three molecules with molecular weights of 26,000, 30,000, and 32,000 under reduced molecular conditions. The data suggest that these molecules could be tumor specific antigens that are involved in the cytotoxicity of cytotoxic T-cells against a human autologous tumor.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000440 Butanols Isomeric forms and derivatives of butanol (C4H9OH). Alcohols, Butyl,Butanol,Butylhydroxides,Hydroxybutanes,Butyl Alcohols
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
March 1997, Immunology letters,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
January 1997, Immunologic research,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
October 1996, Current opinion in immunology,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
March 1996, The Journal of experimental medicine,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
January 1998, Journal of gastroenterology and hepatology,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
July 1986, Journal of immunology (Baltimore, Md. : 1950),
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
May 1998, International journal of cancer,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
May 1996, Cancer research,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
March 2001, Cancer immunology, immunotherapy : CII,
T Sato, and N Sato, and S Takahashi, and M Okubo, and A Yagihashi, and T Torigoe, and N Takahashi, and M Okazaki, and K Asaishi, and K Kukuchi
April 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!